share_log

新興市場銘柄ダイジェスト:ソレイジアは続伸、BUYSELLが急落

Emerging Markets Stock Digest: Solasia continues to rise, BUYSELL plunges.

Fisco Japan ·  Jul 18 14:52

<3907> Silicon Sta 1007 + 3

Continuing to rise. After the close of trading on the 17th, the company announced a share buyback and was well received. It was decided to purchase a maximum of 0.1 million 3900 shares (3.61% of the total number of issued shares excluding treasury shares) through Tokyo Stock Exchange's off-hour trading system (ToSTNeT-3) for treasury stock at 8:45 am on the 18th. The reason for purchasing treasury stock is to enable flexible capital policy in response to changes in the business environment. On the 18th, it was announced that the share buyback was implemented as planned with the maximum number of shares purchased.

<7685> BUYSELL 4025 -460

Rapid decline. After the close of trading on the 17th, the monthly trends for June were announced. The number of inquiries for the business of buying and selling on business trips has turned to a decrease from an increase until the previous month, down 5% compared to the same month of the previous year and is being viewed as a selling point. The reason is that it was temporarily affected by online advertising due to a large-scale promotion by some of the same industry. However, repeat acquisition continues to proceed smoothly, and the number of business trip visits exceeded the previous year.

<3042> SecureVe 326 +12

Rapid rise. On the 17th, Tokyo Gas announced that there was unauthorized access to one of its subsidiaries, resulting in the likelihood of personal information for about 4.16 million general consumers who receive services from the company's outsourcing parent company being leaked. Security-related stocks are being targeted for bargain hunting. The company can provide services such as information security design, construction and operation monitoring, log analysis services, and 24-hour manned response. On the 18th, it also announced the launch of a service that diagnoses the effectiveness of firewall settings from a third-party perspective as a response to the increasing damage caused by ransomware attacks in recent years.

<9241> FLN 1750 +300

Trading suspended at limit up. The introduction of a shareholder benefit program has been announced and well received. It will be implemented for shareholders who own one unit (100 shares) or more recorded in the shareholder register as of August 31, 24. The benefit is a 'maipuru local gift' (selling price 5,000 yen). The 'maipuru local gift' is a catalog gift lineup of locally limited products that utilize attractive information about the region accumulated by 'maipuru' and know-how cultivated by the Furusato Tax payment program. Currently, there are 3 series: Chiba Prefecture version, Funabashi City version, and Kawaguchi City version.

<4579> Rakuria Sosei Pharmaceutical 638 -18

Failed to grow and fell back, but it briefly updated its year-to-date high. After the close of trading on the 17th, it announced a patent evaluation of Nav1.7 and Nav1.8 sodium channel blocking agent (complex ring inducer) in the United States, which is considered a good material. The complex ring inducer tested this time is a novel group of compounds that have blocking effects on Nav1.7 and Nav1.8 sodium channels and are based on a new molecular backbone different from those that have been previously patent evaluated. This patent evaluation enhances intellectual property rights in the United States.

<4597> Solegia 33 +2

Continued growth. After the end of the trading on the 17th, the non-clinical trial results related to the dosage responsiveness of the development product SP-05 (alholichicksorine) were announced, which is considered as good news. Isofol Medical AB, the rights licensor, announced two non-clinical trial results demonstrating the dose responsiveness of alholichicksorine on July 16, 24 (local time), and the results further solidify the hypothesis for the trial design of the phase Ib/II clinical trial, scheduled to begin by the end of 2024, targeting colorectal cancer patients.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment